DK1463735T3 - Imidazo-2,1-B -1,3,4-thiadiazol-sulfonamider - Google Patents
Imidazo-2,1-B -1,3,4-thiadiazol-sulfonamiderInfo
- Publication number
- DK1463735T3 DK1463735T3 DK02784979T DK02784979T DK1463735T3 DK 1463735 T3 DK1463735 T3 DK 1463735T3 DK 02784979 T DK02784979 T DK 02784979T DK 02784979 T DK02784979 T DK 02784979T DK 1463735 T3 DK1463735 T3 DK 1463735T3
- Authority
- DK
- Denmark
- Prior art keywords
- imidazo
- formula
- sulfonamides
- thiadiazole
- thiadiazole sulfonamides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002364985A CA2364985A1 (en) | 2001-12-14 | 2001-12-14 | Imidazo(2,1-b)thiadiazole sulfonamides |
PCT/CA2002/001942 WO2003051890A1 (en) | 2001-12-14 | 2002-12-16 | Imidazo [2,1-b]-1,3,4-thiadiazole suflonamides |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1463735T3 true DK1463735T3 (da) | 2009-12-14 |
Family
ID=4170835
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK02784979T DK1463735T3 (da) | 2001-12-14 | 2002-12-16 | Imidazo-2,1-B -1,3,4-thiadiazol-sulfonamider |
Country Status (11)
Country | Link |
---|---|
US (8) | US7230019B2 (da) |
EP (1) | EP1463735B1 (da) |
JP (2) | JP2005519882A (da) |
AT (1) | ATE439363T1 (da) |
AU (1) | AU2002350333B2 (da) |
CA (1) | CA2364985A1 (da) |
DE (1) | DE60233350D1 (da) |
DK (1) | DK1463735T3 (da) |
ES (1) | ES2329882T3 (da) |
PT (1) | PT1463735E (da) |
WO (1) | WO2003051890A1 (da) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2364985A1 (en) * | 2001-12-14 | 2003-06-14 | John W. Gillard | Imidazo(2,1-b)thiadiazole sulfonamides |
US20060135571A1 (en) * | 2003-06-13 | 2006-06-22 | Jaquith James B | Imidazo(2,1-b)-1,3,4-thiadiazole sulfoxides and sulfones |
JP2006527209A (ja) * | 2003-06-13 | 2006-11-30 | アエジェラ・セラピューティクス・インコーポレーテッド | アシル化及び非−アシル化イミダゾ[2,1−b]−1,3,4−チアジアゾール−2−スルホンアミド及びその使用 |
WO2007034278A2 (en) * | 2005-09-19 | 2007-03-29 | Pfizer Products Inc. | Fused imidazole derivatives as c3a receptor antagonists |
US20090179638A1 (en) * | 2006-02-01 | 2009-07-16 | Aegera Therapeutics Inc. | Assay for identifying inhibitors of neuronal apoptotic pathways |
PT2106260T (pt) | 2007-01-25 | 2018-03-05 | Naia Metabolic Inc | Sensibilizadores de insulina e métodos de tratamento |
HUE025976T2 (en) * | 2007-09-27 | 2016-05-30 | Fund Centro Nac De Investig Oncologicas Carlos Iii | Imidazolothiadiazoles for use as protein kinase inhibitors |
CN102388055B (zh) | 2009-04-02 | 2015-07-29 | 卡洛斯三世国家癌症研究中心基金会 | 咪唑并[2,1-b][1,3,4]噻二唑衍生物 |
US8771324B2 (en) | 2011-05-27 | 2014-07-08 | Globus Medical, Inc. | Securing fasteners |
SI3243826T1 (sl) | 2012-04-26 | 2020-03-31 | Bristol-Myers Squibb Company | Derivati imidazotiadiazola in imidazopirazina kot proteazno aktivirani receptor 4 (PAR4) inhibitorji za zdravljenje agregacije trombocitov |
AU2013251680A1 (en) | 2012-04-26 | 2014-11-13 | Bristol-Myers Squibb Company | Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation |
AU2013251683A1 (en) | 2012-04-26 | 2014-12-18 | Bristol-Myers Squibb Company | Imidazothiadiazole derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation |
EP3053908B1 (en) * | 2013-09-30 | 2018-12-19 | FUJIFILM Corporation | Method for producing alpha-halogenoacetophenon compound, and alpha-bromoacetophenon compound |
US9598419B1 (en) | 2014-06-24 | 2017-03-21 | Universite De Montreal | Imidazotriazine and imidazodiazine compounds |
US9617279B1 (en) | 2014-06-24 | 2017-04-11 | Bristol-Myers Squibb Company | Imidazooxadiazole compounds |
WO2017184520A1 (en) * | 2016-04-18 | 2017-10-26 | Vanderbilt University | Substituted and fused 6-membered protease activated receptor 4 (par-4) antagonists |
WO2020045638A1 (ja) | 2018-08-30 | 2020-03-05 | 日本メジフィジックス株式会社 | 放射性イミダゾチアジアゾール誘導体化合物 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US52514A (en) * | 1866-02-13 | Stove-pipe damper | ||
GB1464259A (en) * | 1975-10-03 | 1977-02-09 | Pfizer Ltd | Imidazo-thiazole and -thiadiazole sulphonamides and their use as therapeutic agents |
US5604202A (en) * | 1990-11-13 | 1997-02-18 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Use of NGF growth factors to treat drug-induced neuropathy |
JP2002516904A (ja) * | 1998-06-03 | 2002-06-11 | ジーピーアイ ニル ホールディングス インコーポレイテッド | N−複素環式カルボン酸またはカルボン酸等配電子体のn−結合スルホンアミド |
CA2364985A1 (en) * | 2001-12-14 | 2003-06-14 | John W. Gillard | Imidazo(2,1-b)thiadiazole sulfonamides |
CA2379375A1 (en) * | 2002-03-28 | 2003-09-28 | Apotex Inc. | Sulfonamide derivatives of 3-substituted imidazol[1,2-d]-1,2,4-thiadiazoles and 3-substituted-[1,2,4] thiadiazolo[4,5-a] benzimidazole as inhibitors of fibrin cross-linking and transglutaminases |
-
2001
- 2001-12-14 CA CA002364985A patent/CA2364985A1/en not_active Abandoned
-
2002
- 2002-12-16 EP EP02784979A patent/EP1463735B1/en not_active Expired - Lifetime
- 2002-12-16 DK DK02784979T patent/DK1463735T3/da active
- 2002-12-16 AT AT02784979T patent/ATE439363T1/de not_active IP Right Cessation
- 2002-12-16 WO PCT/CA2002/001942 patent/WO2003051890A1/en active Application Filing
- 2002-12-16 US US10/498,548 patent/US7230019B2/en not_active Expired - Fee Related
- 2002-12-16 JP JP2003552772A patent/JP2005519882A/ja active Pending
- 2002-12-16 AU AU2002350333A patent/AU2002350333B2/en not_active Ceased
- 2002-12-16 PT PT02784979T patent/PT1463735E/pt unknown
- 2002-12-16 ES ES02784979T patent/ES2329882T3/es not_active Expired - Lifetime
- 2002-12-16 DE DE60233350T patent/DE60233350D1/de not_active Expired - Lifetime
-
2006
- 2006-04-05 US US11/399,010 patent/US7741349B2/en not_active Expired - Fee Related
- 2006-04-06 US US11/399,033 patent/US7772260B2/en not_active Expired - Fee Related
- 2006-04-06 US US11/398,806 patent/US20070021416A1/en not_active Abandoned
-
2007
- 2007-05-07 US US11/797,663 patent/US7714003B2/en not_active Expired - Fee Related
- 2007-05-07 US US11/797,664 patent/US20070238768A1/en not_active Abandoned
- 2007-05-07 US US11/797,665 patent/US7700635B2/en not_active Expired - Fee Related
-
2008
- 2008-04-07 US US12/099,123 patent/US20090042953A1/en not_active Abandoned
-
2009
- 2009-12-22 JP JP2009291135A patent/JP2010106030A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2002350333B2 (en) | 2008-08-21 |
US7714003B2 (en) | 2010-05-11 |
WO2003051890A1 (en) | 2003-06-26 |
EP1463735A1 (en) | 2004-10-06 |
US20090042953A1 (en) | 2009-02-12 |
US20070021476A1 (en) | 2007-01-25 |
US7741349B2 (en) | 2010-06-22 |
DE60233350D1 (de) | 2009-09-24 |
CA2364985A1 (en) | 2003-06-14 |
US20070238768A1 (en) | 2007-10-11 |
US20070088059A1 (en) | 2007-04-19 |
ES2329882T3 (es) | 2009-12-02 |
US20070265319A1 (en) | 2007-11-15 |
US20050069492A1 (en) | 2005-03-31 |
PT1463735E (pt) | 2009-10-15 |
US7700635B2 (en) | 2010-04-20 |
US20070021416A1 (en) | 2007-01-25 |
JP2010106030A (ja) | 2010-05-13 |
US7230019B2 (en) | 2007-06-12 |
JP2005519882A (ja) | 2005-07-07 |
EP1463735B1 (en) | 2009-08-12 |
US7772260B2 (en) | 2010-08-10 |
ATE439363T1 (de) | 2009-08-15 |
AU2002350333A1 (en) | 2003-06-30 |
US20070238766A1 (en) | 2007-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW200612905A (en) | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders | |
MY147767A (en) | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders | |
DK1463735T3 (da) | Imidazo-2,1-B -1,3,4-thiadiazol-sulfonamider | |
GB0225474D0 (en) | Therapeutic agents | |
WO2002036562A3 (en) | 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands | |
ECSP045081A (es) | Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados | |
BR0317020A (pt) | Derivados de hidroxietilamina para o tratamento de doença de alzheimer | |
IS8485A (is) | Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki | |
GB0223038D0 (en) | Therapeutic compounds | |
BR0316350A (pt) | Diaminotriazóis úteis como inibidores de proteìna cinases | |
TW200800976A (en) | New compounds for the treatment of neurological, psychiatric or pain disorders | |
BRPI0316438B8 (pt) | uso de eritropoietina em doenças cardíacas | |
EP1673078A4 (en) | BENZYL ETHER AND BENZYLAMINO BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE | |
EA200300717A1 (ru) | Гетероциклилиндазольные и -азаиндазольные соединения в качестве 5-гидрокситриптамин-6-лигандов | |
BR0316169A (pt) | Derivados de indolil pirazinona úteis para tratamento de distúrbios e doenças hiperproliferativos associados com angiogênese | |
BG108269A (en) | Pyrazolopyrimidines as therapeutic agents | |
ATE385419T1 (de) | Dermatologische und kosmetische zusammensetzungen enthaltend ein furfurylderivat | |
GB0111186D0 (en) | Novel compounds | |
HK1080467A1 (en) | Benzofuran and benzothiophene derivatives useful in the treatment of hyper-proliferative disorders | |
MXPA05008438A (es) | Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6. | |
BR0316723A (pt) | Derivados de anilinopirazol úteis para o tratamento de diabetes | |
WO2002051832A3 (en) | Heterocyclylalkylindole or -azaindole compounds as 5-hydroxytryptamine-6 ligands | |
BG108180A (en) | Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases | |
BRPI0411864A (pt) | combinação de inibidores de src quinase e agentes quimioterápicos para o tratamento de doenças proliferativas | |
MXPA03008635A (es) | Compuestos de dihidropirimidina ciano sustituidos y su uso para tratar enfermedades. |